Literature DB >> 17128557

The treatment of Graves' disease in children.

Scott A Rivkees1.   

Abstract

Graves' disease is the most common form of hyperthyroidism in childhood. Current treatment options include antithyroid medications, surgery, and radioactive iodine. Medical therapy is generally associated with long-term remission rates of less than 25% and a small risk of serious adverse reactions that include hepatic failure and bone marrow suppression. Total thyroidectomy is associated with very high cure rates and a small risk of hypoparathyroidism and recurrent laryngeal nerve damage. When radioactive iodine is used at appropriate doses, there is a very high cure rate without increased risks of thyroid cancer or genetic damage. Clinicians caring for the child or adolescent with Graves' disease are thus faced with using medications with potential short-term and long-term toxicity, for a condition in which spontaneous remission occurs in the minority of pediatric patients. Definitive therapy in the form of surgery or radioactive iodine is necessary and unavoidable for the majority of pediatric patients with Graves' disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17128557     DOI: 10.1515/jpem.2006.19.9.1095

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  11 in total

Review 1.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

2.  Success rate of radioactive iodine treatment for children and adolescent with hyperthyroidism.

Authors:  S Namwongprom; P Dejkhamron; K Unachak
Journal:  J Endocrinol Invest       Date:  2020-06-24       Impact factor: 4.256

3.  Adverse events associated with methimazole therapy of graves' disease in children.

Authors:  Scott A Rivkees; Kerry Stephenson; Catherine Dinauer
Journal:  Int J Pediatr Endocrinol       Date:  2010-03-07

4.  Myopathy Associated with Acute Hypothyroidism following Radioiodine Therapy for Graves Disease in an Adolescent.

Authors:  Valeria C Benavides; Scott A Rivkees
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-14

5.  Nuclear Medicine in Thyroid Diseases in Pediatric and Adolescent Patients.

Authors:  Bilge Volkan-Salancı; Pınar Özgen Kıratlı
Journal:  Mol Imaging Radionucl Ther       Date:  2015-06-05

6.  Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves' disease.

Authors:  Kie Yasuda; Yoko Miyoshi; Makiko Tachibana; Noriyuki Namba; Kazunori Miki; Yukiko Nakata; Toru Takano; Keiichi Ozono
Journal:  Clin Pediatr Endocrinol       Date:  2017-01-31

7.  Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use.

Authors:  Scott A Rivkees; Donald R Mattison
Journal:  Int J Pediatr Endocrinol       Date:  2009-04-21

8.  A Report of Three Girls with Antithyroid Drug-Induced Agranulocytosis; Retrospective Analysis of 18 Cases Aged 15 Years or Younger Reported between 1995 and 2009.

Authors:  Kanshi Minamitani; Junko Oikawa; Kunio Wataki; Kyoko Kashima; Mari Hoshi; Hiroaki Inomata; Setsuo Ota
Journal:  Clin Pediatr Endocrinol       Date:  2011-10-07

9.  Peripheral blood lymphocyte apoptosis and its relationship with thyroid function tests in adolescents with hyperthyroidism due to Graves' disease.

Authors:  Maria Klatka; Ewelina Grywalska; Agata Surdacka; Jerzy Tarach; Janusz Klatka; Jacek Roliński
Journal:  Arch Med Sci       Date:  2012-11-07       Impact factor: 3.318

10.  Impact of methimazole treatment on magnesium concentration and lymphocytes activation in adolescents with Graves' disease.

Authors:  Maria Klatka; Ewelina Grywalska; Malgorzata Partyka; Malgorzata Charytanowicz; Jacek Rolinski
Journal:  Biol Trace Elem Res       Date:  2013-05-11       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.